Simplex Trading
STLN

Simplex Trading’s Starling Oncology STLN Stock Holding History

Simplex Trading’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.5K Buy
12,800
+4,500
+54% +$18.9K ﹤0.01% 5958
2026
Q1 		$25.5K Buy
8,300
+7,800
+1,560% +$23.9K ﹤0.01% 6558
2025
Q4 		$1.78K Buy
+500
New +$1.85K ﹤0.01% 7867

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Simplex Trading's STLN Position: Q1 2026 in Review

Simplex Trading sold out of Starling Oncology (STLN) in Q1 2026, closing a stake of 1,806 shares — an estimated $5.54K sold.

Simplex Trading first reported a position in STLN in Q4 2025 and held it in 1 quarter. The position peaked at $6.43K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Simplex Trading reported no remaining Starling Oncology position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 1,806 Starling Oncology shares in Q1 2026, an estimated $5.54K.
  • Simplex Trading first reported a position in Starling Oncology in Q4 2025 and held it in 1 quarter.
  • Simplex Trading's Starling Oncology position peaked at $6.43K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.